Topic Review
Eudragit® Based Copolymer for Smart Healthcare
Eudragit, synthesized by radical polymerization, is used for enteric coating, precise temporal release, and targeting the entire gastrointestinal system. Evonik Healthcare Germany offers different grades of Eudragit. The ratio of methacrylic acid to its methacrylate-based monomers used in the polymerization reaction defines the final product’s characteristics and consequently its potential range of applications.
  • 636
  • 22 May 2023
Topic Review
Immunomodulatory of Ginseng
Ginseng, a medicinal plant of the genus Panax, boasts a rich historical record of usage that dates back to the Paleolithic period. This botanical is extensively acknowledged and consumed in Eastern countries for its therapeutic properties, and, in Western countries, it is becoming increasingly popular as a remedy for fatigue and asthenia. 
  • 205
  • 22 May 2023
Topic Review
Mood Stabilizers of  First and Second Generation
Mood stabilizers can be classified into two generations based on the chronology of their introduction into the psychiatric armamentarium. First-generation mood stabilizers (FGMS) such as lithium, valproates and carbamazepine were introduced in the years 1960-1970s. Second-generation mood stabilizers (SGMS) started in 1995, with a discovery of the mood-stabilizing properties of clozapine. The SGMS include atypical antipsychotics such as clozapine, olanzapine, quetiapine, aripiprazole, and risperidone as well as a new anticonvulsant drug, lamotrigine. Recently as a candidate for SGMS, a novel antipsychotic, lurasidone, has been suggested. Several other atypical antipsychotics and anticonvulsants, as well as memantine showed some usefulness in the treatment and prophylaxis of bipolar disorder; however, they have not fully met the author’s criteria for mood stabilizers. 
  • 412
  • 19 May 2023
Topic Review
Second-Entry Semisolid Topical Products
The development of second-entry topical products is hampered by several factors. The excipient composition should be similar to the reference product because excipients may also contribute to efficacy. Conventional pharmacokinetic bioequivalence studies were not considered acceptable because drug concentrations are measured downstream after the site of action. There was no agreed methodology to characterize the microstructure of semisolids, and waivers of therapeutic equivalence studies with clinical endpoints were not possible.
  • 242
  • 18 May 2023
Topic Review
Pomegranate Juice for CYP3A4- and CYP2C9-Mediated Drugs Metabolism
The Punica granatum L. (pomegranate) fruit juice contains large amounts of polyphenols, mainly tannins such as ellagitannin, punicalagin, and punicalin, and flavonoids such as anthocyanins, flavan-3-ols, and flavonols. These constituents have high antioxidant, anti-inflammatory, anti-diabetic, anti-obesity, and anticancer activities. Because of these activities, many patients may consume pomegranate juice (PJ) with or without their doctor’s knowledge. This may raise any significant medication errors or benefits because of food-drug interactions that modulate the drug’s pharmacokinetics or pharmacodynamics. 
  • 612
  • 18 May 2023
Topic Review
Paclitaxel in Bioinspired Nanosystems for Targeted Delivery
Taxanes are a class of diterpenes originally isolated from plants of the yew family (Taxaceae). An intriguing alternative to natural vesicles is represented by bioinspired extracellular vesicle (EV)-like nanoparticles (NPs), for example exosomes (EXOs) obtained from a serial extrusion process of a parent cell membrane suspension through decreasing pore size membranes or from hybridization of EXOs and liposome membranes.
  • 312
  • 18 May 2023
Topic Review
Neurotensin and Neurotensin Receptors
The tridecapeptide neurotensin (NT) was isolated from the bovine hypothalamus. It is involved in gut motility and belongs to a family of bioactive peptides, including contulakin, xenopsin, LANT-6, and neuromedin, showing similar amino acid sequences at the C-terminal region; this sequence is essential for the physiological effects mediated by these peptides. Neurotensin is relevant in brain reward mechanisms. Its role in substance abuse needs to be explored in depth to open new therapeutic strategies.
  • 546
  • 17 May 2023
Topic Review
Therapeutic Indications and Mechanisms of Action in Biologics
The year 2022 witnessed the control of the COVID-19 pandemic in most countries through social and hygiene measures and also vaccination campaigns. It also saw a decrease in total approvals by the U.S. Food and Drug Administration (FDA). Nevertheless, there was no fall in the Biologics class, which was boosted through the authorization of 15 novel molecules, thus maintaining the figures achieved in previous years. Indeed, the decrease in approvals was only for the category of small molecules. Monoclonal antibodies (mAbs) continued to be the drug class with the most approvals, and cancer remained the most targeted disease, followed by autoimmune conditions, as in previous years. Interestingly, the FDA gave the green light to a remarkable number of bispecific Biologics (four), the highest number in recent years. Indeed, 2022 was another year without the approval of an antimicrobial Biologic, although important advancements were made in targeting new diseases, which are discussed herein. This work analyzes the Biologics authorized in 2022. Furthermore, the orphan drugs authorized was considered. A quantitative analysis was applied to this year’s harvest, the efficacy of the Biologics with those authorized in previous years was compared. On the basis of their chemical structure, the Biologics addressed fall into the following classes: monoclonal antibodies; antibody-drug conjugates; and proteins/enzymes.
  • 257
  • 17 May 2023
Topic Review
Intravitreal Delivery Systems for Sustained Drug Release
Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy.
  • 638
  • 17 May 2023
Topic Review
Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer
Chitosan nanoparticles (CSNPs) have prospects as a revolutionary delivery system capable of enhancing anticancer drug activity and reducing negative impacts on normal cells. The use of smart drug delivery systems (SDDs) as delivering materials to improve the bioactivity of NPs and to understand the intricacies of breast cancer has garnered significant interest. 
  • 427
  • 16 May 2023
  • Page
  • of
  • 106
Video Production Service